Capsule Summary Slidesets

Share

Program Content

Activities

  • Selinexor + Ruxolitinib for MF
    Phase I Trial of Selinexor With Ruxolitinib in Previously Untreated Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

  • Add-on Parsaclisib in MF
    Phase II Study of Parsaclisib Add-on Therapy in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2022

    Expires: December 13, 2023

  • REFINE: Navitoclax + Ruxolitinib for MF
    REFINE Cohort 3: Combination Therapy With Navitoclax, a Novel BCL-2 Family Inhibitor, and Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2022

    Expires: December 14, 2023

  • Ruxolitinib in CMML
    Phase II Expansion Study of Ruxolitinib for the Treatment of Symptomatic CMML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2022

    Expires: December 12, 2023

  • Sintra-REV Final Results
    Sintra-REV: Final Results of Low-Dose Lenalidomide vs Placebo in Non‒Transfusion Dependent Patients With Low-Risk del(5q) MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2022

    Expires: December 14, 2023

  • MDS Classification Systems Validation
    Retrospective Analysis for Validation of 2022 WHO and ICC Classification Systems for Patients With Myelodysplastic Syndromes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2022

    Expires: December 15, 2023

  • MOMENTUM Update
    MOMENTUM: Updated Analysis of Momelotinib vs Danazol in Symptomatic, Anemic Patients With Myelofibrosis Previously Treated With a JAKi
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2022

    Expires: December 11, 2023

  • Ropeginterferon Alfa-2b in Early MF
    Phase II Study of Ropeginterferon Alfa-2b for Patients With Dynamic International Prognostic Scoring System Low/Intermediate-1–Risk, Prefibrotic Primary MF
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

  • Ruxolitinib in PV and ET
    JAK2 V617F Molecular Response to Long-term Ruxolitinib Therapy in Patients With PV and ET
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2022

    Expires: December 18, 2023

  • STIMULUS-MDS1
    STIMULUS-MDS1: Randomized, Placebo-Controlled Phase II Trial of Sabatolimab, a TIM-3 Inhibitor, Plus HMA in Higher-Risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2022

    Expires: December 12, 2023

Provided by

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen